Solid non‐lung organs from COVID‐19 donors in seropositive or naive recipients: Where do we stand?

Saracco, Margherita; Romagnoli, Renato; Martini, Silvia

doi:10.1111/tid.13761

Cited by 5 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 22 Since then, several transplants have been performed, most of which were liver, kidney, and (to a lesser extent) heart. To date, no cases of SARS-CoV-2 transmission after non-lung transplant have been reported 16 23 6 24 25 7 . 21…”

Section: The Use Of Organs From Deceased Donors With Active Sars-cov-...mentioning

confidence: 99%

“…As of today, in our national experience with 71 organ transplants performed from donors with active SARS-CoV-2 infection and on the basis of current literature with overall 455 non-lung organs (278 kidneys, 125 livers, 41 hearts, and 11 pancreas) transplanted from donors with a positive lower respiratory tract SARS-CoV-2 test, no recipients acquired COVID-19 infection through non-lung transplantation. In contrast there have been three unexpected donor derived transmissions to lung recipients, because the donor tested negative for SARS-CoV-2 in an upper respiratory tract specimen but retrospectively tested positive in a LRT specimen 26 16 23 6 24 25 7 . 21…”

Section: The Use Of Organs From Deceased Donors With Active Sars-cov-...mentioning

confidence: 99%

“… 3 , 6 More than 2 years into the pandemic, many questions remain about how to approach the risk of SARS-CoV-2 donors to recipient transmissibility, but we have to face the need to balance the risk of donor-derived infection with mortality on the waiting list. 7 The aim of this article is to provide an expert opinion and perspective for the use of organs from deceased donors with previous or active SARS-CoV-2 infection from the Italian experience in the absence of more definitive data and international standardized protocols.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 positive donor for solid organ transplantation

Peghin¹,

Grossi²

2022

Journal of Hepatology

View full text Add to dashboard Cite

Section: The Use Of Organs From Deceased Donors With Active Sars-cov-...mentioning

confidence: 99%

Section: The Use Of Organs From Deceased Donors With Active Sars-cov-...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 positive donor for solid organ transplantation

Peghin¹,

Grossi²

2022

Journal of Hepatology

View full text Add to dashboard Cite

“… 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 Although early results appear promising, best practices for utilization of positive SARS‐CoV‐2 donors remain unclear. 7 , 8 , 9 , 11 , 17 , 18 , 19 …”

Section: Introductionmentioning

confidence: 99%

Utilization and outcomes of deceased donor SARS-CoV-2–positive organs for solid organ transplantation in the United States

Schold

Koval

Wee

et al. 2022

American Journal of Transplantation

View full text Add to dashboard Cite

Coronavirus disease‐19 has had a marked impact on the transplant population and processes of care for transplant centers and organ allocation. Several single‐center studies have reported successful utilization of deceased donors with positive severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) tests. Our aims were to characterize testing, organ utilization, and transplant outcomes with donor SARS‐CoV‐2 status in the United States. We used Scientific Registry of Transplant Recipients data from March 12, 2020 to August 31, 2021 including a custom file with SARS‐CoV‐2 testing data. There were 35 347 donor specimen SARS‐CoV‐2 tests, 77.5% upper respiratory samples, 94.6% polymerase chain reaction tests, and 1.2% SARS‐CoV‐2–positive tests. Donor age, gender, history of hypertension, and diabetes were similar by SARS‐CoV‐2 status, while positive SARS‐CoV‐2 donors were more likely African‐American, Hispanic, and donors after cardiac death ( p ‐values <.01). Recipient demographic characteristics were similar by donor SARS CoV‐2 status. Adjusted donor kidney discard (odds ratio = 2.08, 95% confidence interval [CI] 1.66–2.61) was higher for SARS‐CoV‐2–positive donors while donor liver (odds ratio = 0.44, 95% CI 0.33–0.60) and heart recovery (odds ratio = 0.44, 95% CI 0.31–0.63) were significantly reduced. Overall post‐transplant graft survival for kidney, liver, and heart recipients was comparable by donor SARS‐CoV‐2 status. Cumulatively, there has been significantly lower utilization of SARS‐CoV‐2 donors with no evidence of reduced recipient graft survival with variations in practice over time.

show abstract

“…In donors’ liver biopsy at transplantation, SARS-CoV-2 RNA tested negative in 100%, suggesting a very low risk of transmission with LT [ 73 , 74 ]. Notably, none of the recipients testing negative with the molecular test at transplantation was found to be SARS-CoV-2 positive during follow-up [ 95 , 96 ].…”

Section: Viral Infectionsmentioning

confidence: 99%

Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives

et al. 2022

Self Cite

View full text Add to dashboard Cite

End-stage liver disease patients undergoing liver transplantation are prone to develop numerous infectious complications because of immunosuppression, surgical interventions, and malnutrition. Infections in transplant recipients account for the main cause of mortality and morbidity with rates of up to 80%. The challenges faced in the early post-transplant period tend to be linked to transplant procedures and nosocomial infections commonly in bloodstream, surgical, and intra-abdominal sites. Viral infections represent an additional complication of immunosuppression; they can be donor-derived, reactivated from a latent virus, nosocomial or community-acquired. Bacterial and viral infections in solid organ transplantation are managed by prophylaxis, multi-drug resistant screening, risk assessment, vaccination, infection control and antimicrobial stewardship. The aim of this review was to discuss the epidemiology of bacterial and viral infections in liver transplants, infection control issues, as well as surgical frontiers of ex situ liver perfusion.

show abstract

Solid non‐lung organs from COVID‐19 donors in seropositive or naive recipients: Where do we stand?

Cited by 5 publications

References 12 publications

COVID-19 positive donor for solid organ transplantation

COVID-19 positive donor for solid organ transplantation

Utilization and outcomes of deceased donor SARS-CoV-2–positive organs for solid organ transplantation in the United States

Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives

Contact Info

Product

Resources

About